SCHEMBL20072218

SCHEMBL20072218

CC(=S)Nc1cc(C)cc2cnccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 17/20 0.53
MAPT P10636 13/20 0.53
KDM4E B2RXH2 10/20 0.53
KMT2A Q03164 6/20 0.52
SMN1; SMN2 Q16637 9/20 0.49
MEN1 O00255 3/20 0.48
LMNA P02545 7/20 0.46
HTT P42858 5/20 0.46
GALK1 P51570 1/20 0.41
ATM Q13315 1/20 0.41
NSD2 O96028 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 2/20 0.40
BLM P54132 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
APAF1 O14727 1/20 0.40
THRB P10828 1/20 0.39
CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20072220 0.85 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL23841177 0.84 ALDH1A1 (0.50) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL23841183 0.78 KDM4E (0.44) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL20072222 0.74 ALDH1A1 (0.42) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL20072411 0.73 ALDH1A1 (0.41) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL21559903 0.73 ALDH1A1 (0.44) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL8404559 0.71 CYP1A2 (0.52) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL4019913 0.69 CHUK (0.45) ALDH1A1MAPTKDM4EGALK1ATM
SCHEMBL23840987 0.67 ALDH1A1 (0.39) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2
SCHEMBL20072243 0.67 HTT (0.41) ALDH1A1MAPTKDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526239-B1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORP (KR) 2021-11-03 EP disclosed
US-11162104-B2 SCN9A antisense pain killer OLIPASS CORPORATION (KR) 2021-11-02 US disclosed
WO-2018069764-A1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11162104-B2 SCN9A antisense pain killer SCN9A, SCN7A, SCN8A ALDH1A1 3390/4885MAPT 3720/4885KDM4E 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.